Transparency

Mont-Saint-Guibert, Belgium, November 21, 2023, 10.01 pm CET – regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency dated November 17, 2023, indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has crossed the statutory threshold of 50%, holding 22,858,654 shares i.e. 52.19% of Celyad Oncology’s voting rights.

Content of the Notification:

• Reason of the Notification:

Acquisition or disposal of voting securities or voting rights

• Notification by:

A parent undertaking or a controlling person

• Persons subject to the notification requirement:

Fortress Investment Group LLC – 1345 Avenue of the Americas, New York, NY 10105 United States

CFIP CLYD (UK) Limited – 7 Clarges Street, 4th Floor, London W1J 8AE, United Kingdom

• Date on which the threshold is crossed:

November 14, 2023

• Threshold that is crossed (in %):

50

• Denominator:

43,796,947

• Notified details:

A) Voting Rights	Previous notification	After the Transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to the securities	Not linked to the securities	Linked to the securities	Not linked to the securities
Fortress Investment Group LLC	0	0	0	0.00 %	0.00 %
CFIP CLYD (UK) Limited	7,954,808	22,858,654	0	52.19%
Subtotal	7,954,808	22,858,654		52.19%
	TOTAL	22,858,654	0	52.19%	0.00 %

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
	TOTAL			0	0.00%

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	22,858,654	52.19%

• Full chain of controlled undertakings through which the holdings is effectively held:
  • CFIP CLYD (UK) Limited (“CFIP UK”), a United Kingdom limited liability company and a wholly- owned subsidiary of CFIP, directly holds 22,858,654 Ordinary Shares.
  • CFIP CLYD LLC, a Delaware limited liability company (“CFIP”), is the parent of CFIP UK.
  • FIP II UB Investments LP, a Delaware limited partnership (“FIP II”), holds 50% of the membership interests in CFIP.
  • FIP Fund II GP LLC, a Delaware limited liability company (“FIP II GP”), is the general partner of FIP II.
  • Hybrid GP Holdings LLC, a Delaware limited liability company (“Hybrid GP”), is the parent of FIP II GP and indirectly controls the general partners of certain investment funds that hold membership interests in CFIP.
  • FIG LLC, a Delaware limited liability company (“FIG LLC”), indirectly controls the investment advisers to certain investment funds that hold membership interests in CFIP.
  • Fortress Operating Entity I LP, a Delaware limited partnership (“FOE I”), is (i) the sole owner of FIG LLC and (ii) the managing member of, and holds the majority of equity interest in, Hybrid GP.
  • FIG Corp., a Delaware corporation (“FIG Corp.”), is the general partner of FOE I.
  • Fortress Investment Group LLC, a Delaware limited liability company (“Fortress”), is the sole owner of FIG Corp and has no controlling shareholder.

• Additional information:

This transparency notification covers the subscription to 14,903,846 newly issued shares of Celyad Oncology by CFIP CLYD (UK) Limited on 14 November 2023. After the transaction, CFIP CLYD (UK) Limited will hold 22,858,654 shares of Celyad Oncology.

Miscellaneous

• The Press Release may be consulted on the website of Celyad Oncology: https://celyad.com/newsroom/

• The notification can be consulted on the website of Celyad Oncology: https://celyad.com/newsroom/

• Contact person(s):

Any transparency notification must be sent to our Company by email to the attention of Georges Rawadi, Chief Executive Officer (CEO): investors@celyad.com

Mont-Saint-Guibert, Belgium, September 15, 2023, 10.01 pm CET – regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a rectified notification of transparency dated September 13, 2023, indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has crossed the statutory threshold of 25%, holding 7,954,808 shares i.e. 29.99% of Celyad Oncology’s shares and 27.53% voting rights as of September 4, 2023. This press release replaces the press release dated September 7, 2023.

Content of the Notification:

• Reason of the Notification:

Acquisition or disposal of voting securities or voting rights

• Notification by:

A parent undertaking or a controlling person

• Persons subject to the notification requirement:

Fortress Investment Group LLC – 1345 Avenue of the Americas, New York, NY 10105 United States

CFIP CLYD LLC – 1345 Avenue of the Americas, New York, NY 10105 United States

CFIP CLYD (UK) Limited – 7 Clarges Street, 4th Floor, London W1J 8AE, United Kingdom

• Date on which the threshold is crossed:

September 4, 2023

• Threshold that is crossed (in %):

25

• Denominator:

28,893,101

• Notified details:

A) Voting Rights	Previous notification	After the Transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to the securities	Not linked to the securities	Linked to the securities	Not linked to the securities
Fortress Investment Group LLC	0	0	0	0.00 %	0.00 %
CFIP CLYD LLC	6,500,000	0	0	0.00 %	0.00 %
CFIP CLYD (UK) Limited	0	7,954,808	0	27.53%	0.00 %
Subtotal	6,500,000	7,954,808		27.53%
	TOTAL	7,954,808	0	27.53%	0.00 %

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
				0	0.00%
	TOTAL			0	0.00%

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	7,954,808	27.53%

• Full chain of controlled undertakings through which the holdings is effectively held:
  • CFIP CLYD (UK) Limited (“CFIP UK”), a United Kingdom limited liability company and a wholly- owned subsidiary of CFIP, directly holds 7,954,808 Ordinary Shares.
  • CFIP CLYD LLC, a Delaware limited liability company (“CFIP”), is the parent of CFIP UK.
  • FIP II UB Investments LP, a Delaware limited partnership (“FIP II”), holds 50% of the membership interests in CFIP.
  • FIP Fund II GP LLC, a Delaware limited liability company (“FIP II GP”), is the general partner of FIP II.
  • Hybrid GP Holdings LLC, a Delaware limited liability company (“Hybrid GP”), is the parent of FIP II GP and indirectly controls the general partners of certain investment funds that hold membership interests in CFIP.
  • FIG LLC, a Delaware limited liability company (“FIG LLC”), indirectly controls the investment advisers to certain investment funds that hold membership interests in CFIP.
  • Fortress Operating Entity I LP, a Delaware limited partnership (“FOE I”), is (i) the sole owner of FIG LLC and (ii) the managing member of, and holds the majority of equity interest in, Hybrid GP.
  • FIG Corp., a Delaware corporation (“FIG Corp.”), is the general partner of FOE I.
  • Fortress Investment Group LLC, a Delaware limited liability company (“Fortress”), is the sole owner of FIG Corp and has no controlling shareholder.

• Additional information:

This transparency notification covers the following transactions:

• sale of 6,500,000 shares of Celyad Oncology from CFIP CLYD LLC to CFIP CLYD (UK) Limited on 30 August 2023 within the scope of an intragroup share transfer; and
• subscription to 1,454,808 newly issued shares of Celyad Oncology by CFIP CLYD (UK) Limited on 4 September 2023.

After both transactions, CFIP CLYD (UK) Limited will hold 7,954,808 shares of Celyad Oncology.

Miscellaneous

• The Press Release may be consulted on the website of Celyad Oncology: https://celyad.com/newsroom/

• The notification can be consulted on the website of Celyad Oncology: https://celyad.com/investors/regulated-information/

• Contact person(s):

Any transparency notification must be sent to our Company by email to the attention of Georges Rawadi, Chief Executive Officer (CEO): investors@celyad.com

Mont-Saint-Guibert, Belgium, September 12, 2023, 10.01 pm CET – regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a transparency notification dated September 8, 2023, from Tolefi SA and related persons indicating that they have jointly crossed the 20% threshold, holding 6,568,978 shares, or 22.74% of the voting rights of the Company as of September 4, 2023.

Content of the Notification:

• Reason of the Notification:

Threshold crossing by persons acting in concert

• Notification by:

Persons acting in concert

• Persons subject to the notification requirement:

Tolefi SA, Chaussée de Waterloo 1589D, 1180 Uccle

Serge Goblet

Isabelle Thoumyre

Jérôme Goblet

Jean-Daniel Goblet

• Date on which the threshold is crossed:

September 4, 2023

• Threshold that is crossed (in %):

20

• Denominator:

28,893,101

• Notified details:

A) Voting Rights	Previous notification	After the Transaction
	#of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to the securities	Not linked to the securities	Linked to the securities	Not linked to the securities
Tolefi SA	4,591,402	6,504,864	0	22.51%	0.00%
Serge Goblet	56,180	56,180	0	0.19%	0.00%
Isabelle Thoumyre	7,300	7,300	0	0.03%	0.00%
Subtotal	4,654,882	6,568,344		22.73%
Jérôme Goblet	250	250	0	0,00%	0.00%
Jean-Daniel Goblet	384	384	0	0,00%	0.00%
	TOTAL	6,568,978	0	22.74%	0.00%

• Full chain of controlled undertakings through which the holdings is effectively held:

Tolefi SA is 100% owned by Serge GOBLET, Mrs THOUMYRE and their children.

Miscellaneous

• The Press Release may be consulted on the website of Celyad Oncology:
• https://celyad.com/newsroom/

• The notification can be consulted on the website of Celyad Oncology:
• https://celyad.com/investors/regulated-information/

• Contact person(s):

Any transparency notification must be sent to our Company by email to the attention of Georges Rawadi, Chief Executive Officer (CEO): investors@celyad.com

Mont-Saint-Guibert, Belgium, September 7, 2023, 10.01 pm CET – regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency dated September 5, 2023, indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has crossed the statutory threshold of 25%, holding 7,954,808 shares i.e. 29.99% of Celyad Oncology’s shares and 27.53% voting rights as of August 30, 2023.

Content of the Notification:

• Reason of the Notification:

Acquisition or disposal of voting securities or voting rights

• Notification by:

A person that acquires voting rights within the meaning of Article 7 of the Transparency Law and that notifies together with the person that disposes of these voting rights

• Persons subject to the notification requirement:

CFIP CLYD LLC – 1345 Avenue of the Americas, 46th Floor, New York, NY 10105 USA

CFIP CLYD (UK) Limited – 7 Clarges Street, 4th Floor, London W1J 8AE, United Kingdom

• Persons that dispose of voting rights:

CFIP CLYD LLC – 1345 Avenue of the Americas, 46th Floor, New York, NY 10105 USA

• Date on which the threshold is crosses:

August 30, 2023

• Threshold that is crossed (in %):

25

• Denominator:

28,893,101

• Notified details:

A) Voting Rights	Previous notification	After the Transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to the securities	Not linked to the securities	Linked to the securities	Not linked to the securities
CFIP CLYD LLC	6,500,000	0	0	0 %	0 %
CFIP CLYD (UK) Limited	N/A	7,954,808	0	27.53%	0 %
	TOTAL	7,954,808	0	27.53%	0 %

• Full chain of controlled undertakings through which the holdings is effectively held:
  • CFIP CLYD (UK) Limited (“CFIP UK”), a United Kingdom limited liability company and a wholly- owned subsidiary of CFIP, directly holds 7,954,808 Ordinary Shares.
  • CFIP CLYD LLC, a Delaware limited liability company (“CFIP”), is the parent of CFIP UK.
  • FIP II UB Investments LP, a Delaware limited partnership (“FIP II”), holds 50% of the membership interests in CFIP.
  • FIP Fund II GP LLC, a Delaware limited liability company (“FIP II GP”), is the general partner of FIP II.
  • Hybrid GP Holdings LLC, a Delaware limited liability company (“Hybrid GP”), is the parent of FIP II GP and indirectly controls the general partners of certain investment funds that hold membership interests in CFIP.
  • FIG LLC, a Delaware limited liability company (“FIG LLC”), indirectly controls the investment advisers to certain investment funds that hold membership interests in CFIP.
  • Fortress Operating Entity I LP, a Delaware limited partnership (“FOE I”), is (i) the sole owner of FIG LLC and (ii) the managing member of, and holds the majority of equity interest in, Hybrid GP.
  • FIG Corp., a Delaware corporation (“FIG Corp.”), is the general partner of FOE I.
  • Fortress Investment Group LLC, a Delaware limited liability company (“Fortress”), is the sole owner of FIG Corp.

• Additional information:

This transparency notification covers the following transactions:

• sale of 6,500,000 shares of Celyad Oncology from CFIP CLYD LLC to CFIP CLYD (UK) Limited on 30 August 2023 within the scope of an intragroup share transfer; and
• subscription to 1,454,808 newly issued shares of Celyad Oncology by CFIP CLYD (UK) Limited on 4 September 2023.

After both transactions, CFIP CLYD (UK) Limited will hold 7,954,808 shares of Celyad Oncology.

Miscellaneous

• The Press Release may be consulted on the website of Celyad Oncology: https://celyad.com/newsroom/

• The notification can be consulted on the website of Celyad Oncology: https://celyad.com/investors/regulated-information/

• Contact person(s):

Any transparency notification must be sent to our Company by email to the attention of Georges Rawadi, Chief Executive Officer (CEO): investors@celyad.com